216 related articles for article (PubMed ID: 35740881)
1. Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib.
Schlesser C; Meul T; Stathopoulos G; Meiners S
Biomolecules; 2022 May; 12(6):. PubMed ID: 35740881
[TBL] [Abstract][Full Text] [Related]
2. Dissecting bortezomib: development, application, adverse effects and future direction.
Cao B; Li J; Mao X
Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.
Pérez-Galán P; Mora-Jensen H; Weniger MA; Shaffer AL; Rizzatti EG; Chapman CM; Mo CC; Stennett LS; Rader C; Liu P; Raghavachari N; Stetler-Stevenson M; Yuan C; Pittaluga S; Maric I; Dunleavy KM; Wilson WH; Staudt LM; Wiestner A
Blood; 2011 Jan; 117(2):542-52. PubMed ID: 20956803
[TBL] [Abstract][Full Text] [Related]
5. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
[TBL] [Abstract][Full Text] [Related]
6. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.
Weniger MA; Rizzatti EG; Pérez-Galán P; Liu D; Wang Q; Munson PJ; Raghavachari N; White T; Tweito MM; Dunleavy K; Ye Y; Wilson WH; Wiestner A
Clin Cancer Res; 2011 Aug; 17(15):5101-12. PubMed ID: 21712452
[TBL] [Abstract][Full Text] [Related]
7. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
8. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
O'Connor OA
Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324
[TBL] [Abstract][Full Text] [Related]
9. [Proteasome inhibitors].
Alexandre J
Rev Med Interne; 2005 Oct; 26(10):812-5. PubMed ID: 16129520
[TBL] [Abstract][Full Text] [Related]
10. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
12. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
Cvek B; Dvorak Z
Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
[TBL] [Abstract][Full Text] [Related]
13. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition in the treatment of cancer.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Cell Cycle; 2005 Feb; 4(2):290-6. PubMed ID: 15655370
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
Moros A; Rodríguez V; Saborit-Villarroya I; Montraveta A; Balsas P; Sandy P; Martínez A; Wiestner A; Normant E; Campo E; Pérez-Galán P; Colomer D; Roué G
Leukemia; 2014 Oct; 28(10):2049-59. PubMed ID: 24721791
[TBL] [Abstract][Full Text] [Related]
16. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
[TBL] [Abstract][Full Text] [Related]
17. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors.
Cvek B
Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
20. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Weigert O; Pastore A; Rieken M; Lang N; Hiddemann W; Dreyling M
Leukemia; 2007 Mar; 21(3):524-8. PubMed ID: 17268531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
